| Literature DB >> 25477714 |
Woo Seok Yang1, Jaeyoung Ko2, Eunji Kim1, Ji Hye Kim1, Jae Gwang Park1, Nak Yoon Sung1, Han Gyung Kim1, Sungjae Yang1, Ho Sik Rho2, Yong Deog Hong2, Song Seok Shin2, Jae Youl Cho1.
Abstract
21-O-Angeloyltheasapogenol E3 (ATS-E3) is a triterpenoid saponin recently isolated from the seeds of the tea tree Camellia sinensis (L.) O. Kuntze. ATS-E3 has several beneficial properties including anti-inflammatory, antidiabetic, antiatherosclerotic, and anticancer effects. Unlike other phenolic compounds isolated from tea plants, there are no studies reporting the pharmacological action of ATS-E3. In this study, we therefore aimed to explore the cellular and molecular inhibitory activities of ATS-E3 in macrophage-mediated inflammatory responses. ATS-E3 remarkably diminished cellular responses of macrophages such as FITC-dextran-induced phagocytic uptake, sodium nitroprusside- (SNP-) induced radical generation, and LPS-induced nitric oxide (NO) production. Analysis of its molecular activity showed that this compound significantly suppressed the expression of inducible NO synthase (iNOS), nuclear translocation of nuclear factor- (NF-) κB subunits (p50 and p65), phosphorylation of inhibitor of κB kinase (IKK), and the enzyme activity of AKT1. Taken together, the novel triterpenoid saponin compound ATS-E3 contributes to the beneficial effects of tea plants by exerting anti-inflammatory and antioxidative activities in an AKT/IKK/NF-κB-dependent manner.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25477714 PMCID: PMC4245502 DOI: 10.1155/2014/658351
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Chemical structure of ATS-E3.
Primer sequences used for real-time PCR analysis.
| Name | Sequence (5′ to 3′) | |
|---|---|---|
| iNOS | F | CCCTTCCGAAGTTTCTGGCAGCAG |
| R | GGCTGTCAGAGCCTCGTGGCTTTGG | |
| GAPDH | F | CACTCACGGCAAATTCAACGGCA |
| R | GACTCCACGACATACTCAGCAC |
Figure 2The effects of ATS-E3 on macrophage-mediated inflammatory responses. (a) RAW264.7 cells (1 × 106 cells/mL) were treated with ATS-E3 for 6 or 24 h. Cell viability was evaluated using the MTT assay. (b) RAW264.7 cells preincubated with ATS-E3 (left panel) or BAY11-7082 (right panel) were treated with FITC-dextran (1 mg/mL) for 2 h. The level of dextran uptake was determined by flow cytometric analysis. (c) Scavenging effect of ATS-E3 on reactive oxygen species (ROS) generation in sodium nitroprusside- (SNP-) treated RAW264.7 cells was examined by flow cytometric analysis using DHR123 (20 μM) and SNP (0.25 mM). (d) NO inhibitory activities of ATS-E3 (left panel) or L-NAME (right panel) were determined with RAW264.7 cells (1 × 106 cells/mL) treated with LPS (1 μg/mL) in the presence or absence of ATS-E3 or L-NAME for 24 h. The cell culture supernatants were collected, and the concentrations of NO in the supernatants were determined using the Griess assay. * P < 0.05 and ** P < 0.01 compared to control group.
Figure 3Effect of ATS-E3 on the transcriptional activation of RAW264.7 cells during TLR signaling. (a) The level of iNOS mRNA in RAW264.7 cells treated with ATS-E3 (0 to 10 μM) in the presence or absence of LPS (1 μg/mL) for 6 h was determined by real-time quantitative RT-PCR. ((b) and (c)) HEK293 cells cotransfected with NF-κB-Luc and β-gal (as a transfection control) plasmid constructs were treated with ATS-E3 under the cotransfection conditions with FLAG-MyD88 or Myc-Syk (1 μg/mL each) for 12 h. Luciferase activity was determined using luminometery, as described in Section 2. (d) RAW264.7 cells (5 × 106 cells/mL) were incubated with LPS (1 μg/mL) in the presence or absence of ATS-E3 for the indicated times. After preparing the nuclear fractions, the translocated levels of total transcription factors (p65, p50, and lamin A/C) were identified using immunoblotting. Relative intensity was calculated using total levels by the DNR Bio-Imaging System. ** P < 0.01 compared to control group.
Figure 4Effect of ATS-E3 on the activation of NF-κB upstream signaling cascades. ((a) and (b)) Total and phosphoprotein levels of PDK1, AKT, IKKα/β, and β-actin in whole cell lysates of LPS-treated RAW264.7 cells were determined by immunoblotting analysis. (c) Kinase activities of PDK1 and AKT1 were determined by a direct kinase assay using purified enzymes. The value of the control, which received vehicle treatment, was set as 100% activity for each enzyme (PDK1 or AKT1). (d) NO inhibitory activities of standard compounds (BAY11-7082 (BAY), LY294002 (LY), and wortmannin (Wort)) were determined in RAW264.7 cells (1 × 106 cells/mL) treated with LPS (1 μg/mL) in the presence or absence of standard compounds for 24 h. Relative intensity was calculated using total levels by the DNR Bio-Imaging System. * P < 0.05 and ** P < 0.01 compared to control group.
Figure 5Putative inhibitory pathway of macrophage-mediated inflammatory responses by ATS-E3.